A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

NCT00162500 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Tumors

Interventions

BIOLOGICAL: Peptide Vaccine (MUC-1)

Sponsor

Hadassah Medical Organization

Collaborators

[object Object]